TD Cowen downgraded Cytek Biosciences (CTKB) to Hold from Buy with a price target of $4, down from $7. The company’s Q1 missed as multiple headwinds persist and the fiscal 2025 guidance was lowered, the analyst tells investors in a research note. The firm says that while Cytek remains a dominant flow cytometry player, it would stay on the sidelines pending better clarity on a path back to sustained growth.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences Faces Revenue Challenges and Market Uncertainty, Downgraded to Hold
- Cytek Biosciences Reports Q1 2025 Financial Results
- Cytek Biosciences reports Q1 EPS (9c) vs. (5c) last year
- Cytek Biosciences cuts FY25 revenue view to $196M-$210M from $204M-$212M
- Cytek Biosciences: Hold Rating Amid Revenue Decline and Macroeconomic Uncertainties